Pfizer Inc
Vaccine stocks fall after key FDA official resigns in protest of RFK Jr.
Rafael Henrique | Lightrocket | Getty Images Shares of major vaccine makers dropped on Monday after a key U.S. health official resigned in protest of Health and Human Services Secretary Robert F. Kennedy Jr.’s views on immunization. The departure of Peter Marks, the Food and Drug Administration’s top vaccine regulator, has raised fresh fears about […]
Read More
Eli Lilly will soon release key data on its weight loss pill. Here’s why it could be a game-changer
A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images Patients, doctors and investors will soon learn a lot more about a new, more convenient treatment that could shake up the booming weight loss drug market. Eli Lilly plans to […]
Read More
Beijing pledges greater market access as top global CEOs gather at the China Development Forum
Chinese Vice Premier He Lifeng (R) shakes hands with US Senator Steve Daines before a meeting held in the Xinjiang Room at the Great Hall of the People in Beijing on March 22, 2025. Ng Han Guan | Afp | Getty Images China’s Vice Premier He Lifeng has reassured foreign business leaders that Beijing will […]
Read More
Pro-Trump senator meets Chinese Premier Li with U.S. executives
Chinese Premier Li Qiang (R) greets Pfizer CEO Albert Bourla from a delegation led by US Senator Steve Daines before a meeting held in the Fujian Room at the Great Hall of the People in Beijing on March 23, 2025. Ng Han Guan | Afp | Getty Images U.S. Republican Senator Steve Daines met Chinese […]
Read More
An all weather investment that’s consistently positive for those tired of the market roller coaster
The first member of the CNBC Pro All Weather Stock list is a surprisingly resilient exchange-trade fund that offers high dividend income to boot. The timing is right for this list in particular because of the precarious set-up of the stock market so far in 2025. We’ll be adding to it periodically as the year […]
Read More
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
Sopa Images | Lightrocket | Getty Images Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday, marking the end of the Bluebird’s fall from the one of the buzziest biotech firms to one that was on the cusp of running out of money. […]
Read More
Goldman’s portfolio of hedge fund favorites is trouncing the market this year. Here’s what’s in it
While the S & P 500 is trading close to its all-time high, a group of favored stocks among hedge funds is soaring even higher, according to Goldman Sachs. The S & P 500 reached an all-time intraday high as well as a new closing record on Wednesday, the broad market index’s second consecutive record […]
Read More
Trump is unlikely to end Medicare drug price talks — here’s what that means for patients and pharma
President Donald Trump arrives in the Brady Press Briefing Room at the White House on Jan. 30, 2025 in Washington, DC. Oliver Contreras | Afp | Getty Images President Donald Trump likely won’t do away with a landmark process that allows Medicare to negotiate drug prices with manufacturers, even as he moves to erase Joe […]
Read More
Bristol Myers’ stock decline in response to weak guidance is a gift to investors
Bristol Myers Squibb on Thursday reported better-than-expected quarterly results, but weak guidance for 2025 sent shares lower. Jim Cramer’s faith in the drugmaker is unshaken. Revenue in the fourth quarter rose 8% year over year to $12.34 billion, well ahead of the $11.57 billion consensus, according to analysts’ estimates compiled by LSEG. Adjusted earnings per […]
Read More
Bristol Myers Squibb plans $2 billion in cost cuts by 2027, issues weak guidance
The Bristol Myers Squibb research and development center at Cambridge Crossing in Cambridge, Massachusetts, on Dec. 27, 2023. Adam Glanzman | Bloomberg | Getty Images Bristol Myers Squibb on Thursday said it will slash $2 billion in costs by the end of 2027, expanding its ongoing cost savings effort to chart a path toward long-term […]
Read More